Background Atrial fibrillation (AF) is linked to significant morbidity and mortality, with ischaemic stroke being a leading ...
Background Biochemical markers of inflammation, coagulation and myocardial stress have been associated with both prevalent ...
Despite previous success in oncology, the monoclonal antibody does not improve heart failure health status or physical ...
BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study. The study showed that acoramidis ...
At 24 weeks, the first secondary endpoint -- a composite requiring multicomponent improvement from baseline in 6-minute walk ...
By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo- Acoramidis significantly reduced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback